Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
VioQuest Pharmaceuticals, Inc. (VOQP)
Basking Ridge, NJ, US
VioQuest Pharmaceuticals, Inc. is a biopharmaceutical entity that concentrates on obtaining, developing, and marketing drug therapies in clinical stages, specifically targeting oncology and infectious diseases. Its primary product, Xyfid, is currently being advanced for both the management and prevention of hand-foot syndrome. The company's pipeline also features VQD-002, a nucleoside analog presently in Phase I clinical trials for cancer treatment. Another key compound is Lenocta, a small molecule designed to inhibit various protein tyrosine phosphatases, which is progressing through Phase IIa clinical studies for indications like melanoma, renal cell carcinoma, and other solid tumors. Beyond its therapeutic drug development, VioQuest Pharmaceuticals offers chiral products, specialized technology, and bespoke synthesis development services. These services are provided to pharmaceutical and fine chemical companies at different stages of their product lifecycles. The firm was established in 2000 and operates from its corporate headquarters in Basking Ridge, New Jersey.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -62.50% | -62.50% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-12.0% Q2'08: +57.4% (vs Q2'07)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%—
-
Share dilution Biotechnology: -3.4%+17.4% Q2'08: +6.5% (vs Q2'07)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.44× Q2'08: 0.00× (vs Q2'07)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2008-07-21 | SCHNITTKER CHRISTOPHER P | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2008-06-13 | WEISER MICHAEL | Director | D-Return | D | Stock Option | 1,290 | 19.60 | 25.3K | 0 | — | ↗ |
| 2008-03-14 | WEISER MICHAEL | Director | C-Conversion | D | Senior Convertible Promissory Notes | 2,631 | 3.80 | 10.0K | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mark D. Dacko | Controller and Assistant Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VOQP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
